Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044323 | 0.87 | MAPT (0.48) | KDRRIPK1 | |
| SCHEMBL14707505 | 0.85 | SMARCA2 (0.52) | TRPV1 | |
| SCHEMBL13552856 | 0.84 | GRM4 (0.51) | RIPK1TRPV1GRM4 | |
| SCHEMBL13552722 | 0.84 | MEN1 (0.56) | KDRTRPV1 | |
| SCHEMBL13552997 | 0.83 | NPC1 (0.63) | KDRGRM4AURKB | |
| SCHEMBL13552995 | 0.82 | MEN1 (0.54) | KDRTRPV1 | |
| SCHEMBL13553001 | 0.81 | PTPN7 (0.45) | RIPK1TRPV1 | |
| SCHEMBL13552728 | 0.80 | TRPV1 (0.48) | KDRRIPK1TRPV1GRM4 | |
| SCHEMBL13552747 | 0.80 | POLB (0.50) | TRPV1GRM4 | |
| SCHEMBL13043161 | 0.79 | GRM4 (0.61) | KDRGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | KDR 1260/4885RIPK1 1701/4885TRPV1 3668/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | KDR 191/4885RIPK1 445/4885TRPV1 3560/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | KDR 1260/4885RIPK1 1701/4885TRPV1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.